Benefits of TTR Gene Silencers

EP: 1.Overview of hATTR Amyloidosis

EP: 2.Prevalence of hATTR Amyloidosis

EP: 3.Disparities in Prevalence of hATTR Amyloidosis

EP: 4.Signs and Symptoms of hATTR Amyloidosis

EP: 5.Diagnosing hATTR Amyloidosis

EP: 6.Diabetes and hATTR Amyloidosis Neuropathy

EP: 7.Diagnostic Strategies in hATTR Amyloidosis

EP: 8.Genetic Testing in hATTR Amyloidosis

EP: 9.Tissue Biopsies in hATTR Amyloidosis

EP: 10.Identification of the Amyloid Protein 

EP: 11.Recent Advances in hATTR Amyloidosis Treatment

EP: 12.Evaluating hATTR Amyloidosis Therapy

Now Viewing

EP: 13.Benefits of TTR Gene Silencers

EP: 14.Evaluating the Potential of Vultrisiran

EP: 15.Future Treatment of hATTR Amyloidosis

John L. Berk, MD: Dr Polydefkis, Dr Witteles suggested that the earlier the better with most effective therapy, alluding to TTR gene silencers. Let’s say I have fairly advanced, previously undiagnosed TTR amyloid neuropathy. I’m seeking your advice; am I out of luck in terms of getting benefits from the TTR gene silencers?

Michael J. Polydefkis, MD: No. It’s been shown that irrespective of neuropathy severity, you’ll still experience a benefit from silencer therapy. This means that your disease will be likely halted. You may not improve dramatically, you may not go from a cane to running marathons, but you won’t regress to 2 canes or to a wheelchair.

John L. Berk, MD: Thank you for watching this NeurologyLive® Peer Exchange. If you enjoyed the content, please subscribe to our e-newsletters to receive upcoming Peer Exchanges and other great content right in your inbox.

Transcript Edited for Clarity